Oglufanide (H-Glu-Trp-OH) is a dipeptide immunomodulator isolated from calf thymus. Oglufanide inhibits vascular endothelial growth factor (VEGF) . Oglufanide can stimulate the immune response to hepatitic C virus (HCV) and intracellular bacterial infections. Oglufanide shows antitumor and anti-angiogenesis activities In Vitro Oglufanide (IM862) (1-1000 μg/mL) exhibits dose dependent inhibition of angiogenesis in the chorioallantoic membrane assay with complete inhibition of β-FGF and VEGF-induced angiogenesis. ?\nOglufanide (L-glu-L-trp) (0-1000 μg/mL; 5 days) has no effect on the viability of either the tumor cell lines or HUVECs . MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Oglufanide (L-glu-L-trp) (1-100 mg/kg/day; s.c.; 10 days) has antitumor activity in immunocompetent and immunodeficient mice. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: C57BL/6 immune competent mice, Lewis lung carcinoma (LLC) xenograft; Balb/C athymic mice, M21 human melanoma xenograftDosage: 1, 10, 50 and 100 mg/kg/day Administration: Subcutaneous injection, 10 days Result: Resulted in a dose-dependent inhibition of LLC tumor growth in syngeneic immune competent mice and showed a dose-dependent decrease in tumor volumes of xenografts in Balb/C athymic mice implanted with M21 human melanoma cells. Form:Solid IC50& Target:VEGFR|HCV|Human Endogenous Metabolite